

Trastuzumab duocarmazine

Cat. No.:	HY-P99547
CAS No.:	1642152-40-6
Target:	Antibody-Drug Conjugates (ADCs)
Pathway:	Antibody-drug Conjugate/ADC Related
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.

BIOLOGICAL ACTIVITY

Description	Trastuzumab duocarmazine ((vic)-Trastuzumab duocarmazine) is a HER2-targeting ADC that is recognized and cleaved by histone B in tumor cells and selectively targets tumor cells. Trastuzumab duocarmazine has anti-tumor activity and can be used in cancer research related to uterine and ovarian sarcomas ^[1] .
In Vitro	Trastuzumab duocarmazine (SYD985) (0.0001-100 µg/mL, 24 h) is lethal to both HER2 ⁻ and HER2 ⁺ cells, and is 7-fold more lethal to HER2/NEU ³⁺ cell lines with the IC ₅₀ value of 0.013 µg/mL compared to T-DM1 with the IC ₅₀ value of 0.096 µg/mL. More importantly, in HER2/NEU ¹⁺ cells, it is 54 times more potent in killing cells compared to T-DM1 ^[1] . MCE has not independently confirmed the accuracy of these methods. They are for reference only.
In Vivo	Trastuzumab duocarmazine (SYD985) (3 mg/kg or 10 mg/kg, i.v., once) significantly inhibits tumor growth and prolongs the survival cycle in CB-17 / SCID mice with HER2/neu 3+ cells, with effective in vivo anti-tumor activity ^[1] . MCE has not independently confirmed the accuracy of these methods. They are for reference only.

REFERENCES

[1]. Gulden Menderes, et al. SYD985, a Novel Duocarmycin-Based HER2-Targeting Antibody-Drug Conjugate, Shows Antitumor Activity in Uterine and Ovarian Carcinosarcoma with HER2/Neu Expression. Clin Cancer Res. 2017 Oct 1;23(19):5836-5845.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA